Featured projects

  • Characterization of duvelisib activity in follicular lymphoma and macrophages crosstalk

    Principal investigator: Patricia Pérez Galán.
    Funder: Janssen Pharmaceuticals .
    Duration: 01/01/2020 - 31/12/2020
  • Multi-cellular interactions in the progression of chronic inflammatory diseases and lymphoproliferative disorders: 3D models to investigate targeted immune therapies -3DIMMUNETARGET

    Principal investigator: Maria Cinta Cid Xutgla, Patricia Pérez Galán.
    Funder: Ministerio de Economia y Competitividad (MINECO) .
    Code: SAF 2017- 88275-R.
    Duration: 01/01/2018 - 31/12/2020
  • Cross-border network of personalized immunotherapies in Non-Hodgkin Lymphoma -IMLINFO (POCTEFA-INTERREG).

    Principal investigator: Patricia Pérez Galán.
    Funder: INTERREG V-POCTEFA .
    Code: EFA281/16.
    Duration: 01/01/2018 - 31/12/2021
  • Crosstalk between lymphocytes and their microenvironment in chronic inflammatory diseases and lymphoproliferative disorders as a target for new therapeutic intervention

    Principal investigator: Patricia Pérez Galán.
    Funder: Institut d`Investigacions Biomèdiques August Pi i Sunyer (Sede o evento); Ministerio de Economia y Competitividad (MINECO) ; PROYECTOS I+D+I RETOS INVESTIGACIÓN (Programa financiador competitivo).
    Code: SAF2014-57708-R.
    Duration: 01/10/2015 - 30/09/2018
  • Crosstalk between lymphocytes and their microenvironment in chronic inflammatory diseases and lymphoproliferative disorders as a target for new therapeutic intervention

    Principal investigator: Patricia Pérez Galán.
    Funder: Ministerio de Economía y Competitividad .
    Code: SAF 2014/57708R.
    Duration: 01/01/2015 - 01/01/2017
  • Characterization of the mechanisms of microenvironment-derived resistance to GS-1101/ Idelalisib in follicular lymphoma. Analysis of therapeutic potential combination with other kinases inhibitors

    Principal investigator: Patricia Pérez Galán.
    Funder: Gilead .
    Duration: 01/07/2014
  • HuMax-CD38 (Daratumumab) activity in in vivo models of MCL and FL: Analysis of possible combinatorial regimens

    Principal investigator: Patricia Pérez Galán.
    Funder: Janssen Pharmaceuticals .
    Duration: 01/06/2014
  • Targeting proliferation and tumor-microenvironment interactions using bifunctional compounds against cannabinoid and chemokine receptors

    Principal investigator: Patricia Pérez Galán.
    Funder: Fundacio la Marato TV3 .
    Duration: 26/05/2014 - 26/05/2017
  • Hemafarma: Pharmaceutical development of based on apoptosis for hematological cancers classified as rare diseases

    Funder: Institut d`Investigacions Biomèdiques August Pi i Sunyer (Sede o evento); Ministerio de Economía y Competitividad ; INNPACTO (Programa financiador competitivo).
    Code: ipt.2012-0673-010000.
    Duration: 01/01/2013 - 31/12/2014
  • Targeting the interaction between the tumor cell and its microenvironment: a new therapeutic approach for the treatment of Follicular Lymphoma

    Principal investigator: Patricia Pérez Galán.
    Funder: Institut d`Investigacions Biomèdiques August Pi i Sunyer (Sede o evento); Ministerio de economica y competitividad ; proyectos de investigacionno orientada (Programa financiador competitivo).
    Code: SAF 2011-29326.
    Duration: 01/01/2012 - 31/12/2014